Moderna (MRNA) PT Lowered to $78 at UBS
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $174.38 +176.97%
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
6 Buy, 21 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $78.00 (from $96.00) while maintaining a Buy rating.
You May Also Be Interested In
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- CIBC Downgrades Bank of Montreal (BMO:CN) (BMO) to Neutral
- Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) Following Positive Intismeran Data
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
